Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug ...
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) ...
Shandong Boan Biotechnology Company., Limited. Class H ( (HK:6955)) has issued an announcement. Shandong Boan Biotechnology Co., Ltd. announced that its Marketing Authorisation Applications for two ...
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...
Maryam Rashid Al Habsi, a mother of eight, was 29 weeks pregnant with her youngest child when she was diagnosed with breast cancer. What she thought was normal swelling linked to pregnancy, turned out ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
At 49, Derek Wilks was a picture of health. The accountant from Purley, in south London, had run marathons around the world and kept himself fit with regular training. But one morning he felt a sharp ...
The human heart has a limited capacity for self-repair because, unlike most other cells, cardiomyocytes do not regenerate. Therefore, if a substantial number of myocytes is lost after a myocardial ...
Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. “I am humbled to be working alo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback